|
Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
Hundo Cho, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Yong Won Choi, Tae-Hwan Kim, Mi Sun Ahn, Chul-Ho Kim, Yoo Seob Shin, Jeon Yeob Jang, Young-Taek Oh, Jaesung Heo, Seung Soo Sheen
Korean J Intern Med. 2022;37(6):1269 Published online November 1, 2022
|
|
|
Hemato-oncology
Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
[corrected-article]
Hundo Cho, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Yong Won Choi, Tae-Hwan Kim, Mi Sun Ahn, Chul-Ho Kim, Yoo Seob Shin, Jeon Yeob Jang, Young-Taek Oh, Jaesung Heo, Seung Soo Sheen
Korean J Intern Med. 2022;37(3):653-659. Published online April 20, 2022
Background/Aims: The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence
Methods: Two hundred and fifty-seven patients who started CC..
|
|
|
The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
Jin-Hyuk Choi, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Mi Sun Ahn, Young-Taek Oh, O kyu Noh, Se-Hyuk Kim, Tae Hoon Roh, Seung Soo Sheen
Korean J Intern Med. 2022;37(2):434-443. Published online February 16, 2022
Background/Aims: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined.
Methods: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-..
|
|
|
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
Korean J Intern Med. 2017;32(3):422-428. Published online March 30, 2017
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studi..
|
|
|
